Biofrontera Submits Ameluz SNDA For Expanded Actinic Keratosis Use
(RTTNews) - On Thursday, Biofrontera Inc. (BFRI) said it has submitted a supplemental New Drug Application (sNDA) to the U.S. FDA seeking to expand the approved use of Ameluz in combination with photodynamic therapy (PDT) for the treatment of actinic keratoses (AKs).